Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 1.50% on September 22, with a trading volume of 1.263 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of September 19, 2024, the fund's latest share count was 8.17 billion shares, with a total size of 7.676 billion yuan, reflecting a year-to-date increase of 1966.38% in shares and 1931.78% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 87.92% during the management period [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The cumulative trading amount over the last 20 trading days reached 37.235 billion yuan, with an average daily trading amount of 1.862 billion yuan [1][2]

Market Performance - Hong Kong stocks experienced fluctuations in early trading, with technology stocks showing mixed performance, while consumer electronics and pharmaceuticals led the gains [1] - Notable gainers included Hongteng Precision, which rose over 12%, and companies like Sunny Optical Technology and AAC Technologies, which increased by over 3% [1] - The Hong Kong Technology 50 ETF (159750) rose by 0.42%, with nearly 40 million CNY in trading volume [2] Investment Trends - Over the past five trading days, the ETF saw a continuous net inflow of 186 million CNY, reaching a new high of 1.211 billion CNY in total assets [1] - Foreign capital continued to flow into Chinese assets, with a net inflow of 1.86 billion USD into offshore Chinese stocks, marking the highest weekly inflow since November of the previous year [5] Economic Context - The U.S. Federal Reserve's recent decision to cut interest rates by 25 basis points is seen as a "preventive rate cut," with indications of an additional 50 basis points of potential cuts within the year [3] - Historical data suggests that after the Fed initiates or resumes preventive rate cuts, the probability of subsequent increases in both A-shares and Hong Kong stocks significantly rises [3][4] Sector Analysis - The Hong Kong Technology Index (931674) has outperformed the Hang Seng Technology Index, with a cumulative increase of 131.68% since its base date compared to the 109.81% increase of the Hang Seng Technology Index [7]

Market Overview - A-shares saw a late rally with the Sci-Tech 50 Index rising over 3%, while Hong Kong stocks showed weakness with both major indices down over 1% [1] - The Shanghai Composite Index closed up 0.22% at 3828.58 points, the Shenzhen Component Index rose 0.67% to 13157.97 points, and the ChiNext Index increased by 0.55% to 3107.89 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 21,427 billion yuan, a decrease of over 2,000 billion yuan from the previous day [1] Sector Performance - The semiconductor sector showed strong performance, with several stocks reaching new highs, including Chipone Technology, which rose over 17% to surpass 200 yuan [3] - Consumer electronics stocks were active, with Longying Precision hitting the daily limit and achieving a new historical high [6][8] - The AI industry chain stocks also saw gains, with Guangku Technology rising over 10% and Industrial Fulian increasing nearly 7% [1] Notable Stocks - Tianpu Co. achieved a 14-day consecutive limit-up, breaking the 100 yuan mark [1] - Yunnan Tourism also recorded a limit-up, marking its fourth consecutive increase [10] - In Hong Kong, Hongteng Precision surged nearly 18%, approaching historical highs, while Sunny Optical Technology rose nearly 7% [2] Semiconductor Industry Insights - The domestic semiconductor equipment localization rate has been steadily increasing, with a significant gap of approximately 3 million GPU cards in China [5] - Long-term prospects indicate that domestic wafer fabs could expand their market share from about 10% to 30%, indicating a threefold growth potential [6] - The semiconductor equipment localization rate is currently around 20%, with potential growth to 60%-100%, suggesting a significant development trend [6] Consumer Electronics Developments - The period from September to October is noted as a peak for new product launches in the consumer electronics sector, with companies in the supply chain positioned for potential rebounds [8] - Meta recently held its Meta Connect 2025 conference, unveiling several new hardware products, including AR glasses and AI glasses [8]

Financial Performance - Revenue for the first half of 2025 reached RMB 9,953,216 thousand, a 16.1% increase from RMB 8,574,214 thousand in 2024[11] - Gross profit increased by 27.0% to RMB 4,252,852 thousand, compared to RMB 3,349,951 thousand in the previous year[11] - Adjusted net profit rose by 11.6% to RMB 2,839,986 thousand, up from RMB 2,544,800 thousand in 2024[11] - Revenue for the six months ended June 30, 2025, increased by 16.1% year-on-year to RMB 9,953.2 million[17] - Gross profit rose by 27.0% year-on-year to RMB 4,252.9 million, with a gross margin improvement of approximately 3.6%[17] - Net profit attributable to the company increased by 54.8% year-on-year to RMB 2,756.6 million, while net profit attributable to shareholders rose by 56.0% to RMB 2,339.3 million[17] - Total revenue for the six months ended June 30, 2025, was approximately RMB 9,953.2 million, up from RMB 8,574.2 million in the previous year[60] - Gross profit increased by 27.0% to approximately RMB 4,252.9 million, with a gross margin rising from 39.1% to 42.7%[62] - The group's net profit increased by 54.8% from approximately RMB 1,780.3 million for the six months ended June 30, 2024, to approximately RMB 2,756.6 million for the six months ended June 30, 2025[72] - The net profit margin rose from 20.8% to 27.7% during the same period, primarily due to increased gross profit and investment income from the group's investment portfolio[72] Project and Operational Growth - The total number of ongoing integrated projects reached 864, with 86 new projects added in the reporting period[14] - The number of preclinical projects increased to 429, while early clinical projects rose to 344, indicating sustainable growth[14] - The company successfully secured 9 external projects during the reporting period, including 2 late-stage clinical projects[14] - The total amount of uncompleted orders as of June 30, 2025, increased to USD 20.3 billion, including USD 11.4 billion in service orders and USD 9.0 billion in potential milestone payment orders[17] - The company has empowered over 660 IND submission projects, reducing the development cycle from DNA to IND to just nine months[25] - The proprietary WuXiaTM platform has delivered over 1,000 cell lines and can empower 150 comprehensive CMC projects annually, making it one of the largest platforms in the industry[25] - The WuXiUPTM platform has been applied to develop over 170 processes for more than 60 molecules, achieving production capacities of 20 to 120 g/L[26] - The number of late-stage clinical and commercial production projects reached 67 and 24, respectively, by the end of the reporting period, with two new late-stage projects acquired[31] Financial Position and Assets - Total assets increased by 6.1% to RMB 60,437,387 thousand, compared to RMB 56,977,435 thousand at the end of 2024[11] - Total liabilities decreased by 1.1% to RMB 11,372,316 thousand, down from RMB 11,499,866 thousand[11] - Cash and cash equivalents stood at RMB 8,439,058 thousand, reflecting a 1.9% increase from RMB 8,279,182 thousand[11] - The company's property, plant, and equipment balance grew by 6.7% from approximately RMB 26,070.5 million to approximately RMB 27,815.9 million, driven by ongoing construction in Singapore and currency appreciation in Europe[74] - Inventory increased by 8.8% from approximately RMB 1,521.7 million to approximately RMB 1,655.0 million, attributed to stockpiling for business expansion in Europe[82] - Trade and other receivables rose by 23.7% from approximately RMB 6,240.7 million to approximately RMB 7,721.2 million, reflecting business expansion and revenue growth[84] Regulatory and Compliance - The company successfully passed 44 regulatory inspections since 2017, including 22 from the EU EMA and US FDA, with no major issues found[37] - The company is actively monitoring global regulatory changes to adapt to evolving compliance requirements in the biopharmaceutical industry[120] - Data compliance has become a critical issue, with the company monitoring risks associated with data protection and compliance plans[127] - The company has received ISO 22301 certification for business continuity management, covering all business functions[129] Shareholder and Equity Information - The total number of issued shares as of June 30, 2025, is 4,068,902,309[132] - Dr. Li Ge holds 509,962,633 shares, representing 12.53% of the total equity[138] - Life Science Holdings, Life Science Limited, and WuXi PharmaTech collectively hold 501,251,133 shares, accounting for 12.32% of the total equity[138] - BlackRock, Inc. holds 208,273,538 shares, which is 5.12% of the total equity[138] - The company has a pre-IPO share option plan with a total of 121,477,019 shares available for issuance, approximately 2.98% of the total issued shares[141] - The board decided not to declare any interim dividend for the six months ended June 30, 2025[110] Employee and Talent Management - Employee costs for the six months ended June 30, 2025, were approximately RMB 2,586.6 million, an increase from RMB 2,295.2 million in the same period of 2024, reflecting a growth of 12.7%[107] - The company maintained a key talent retention rate of approximately 98.8%[107] - The company has implemented various employee incentive plans to reward contributions from eligible participants[107] Investment and Capital Management - The company raised approximately RMB 10,899.0 million from the fourth placement, with 40% allocated for acquiring additional DS/DP production capacity and another 40% for establishing large-scale production capabilities for various technology platforms[170] - The company invested RMB 1,035.8 million in mRNA-related technologies, which accounts for 10% of the total raised funds[170] - The company repurchased a total of 60,539,500 shares during the reporting period, with a total purchase price of approximately HKD 1,110.62 million[172] - The repurchase was conducted to demonstrate confidence in the company's business outlook, as the current trading price did not reflect its intrinsic value[172] Risk Management - The company faces interest rate risks related to fixed and floating rate bank borrowings and deposits, which are managed through regular assessments of potential impacts[123] - The group generates most of its revenue from sales denominated in USD, while procurement costs are settled in RMB, USD, and EUR, exposing it to foreign exchange risk[126] - The group has established forward contracts to manage foreign exchange risk and has adopted hedge accounting for derivatives[126] - The group faces maximum credit risk from financial assets listed at their carrying value on the consolidated balance sheet[124]

港股三大指数全天水下震荡，盘中跌幅均一度扩大逾1%。截止收盘，恒生指数跌0.76%或200.96点，报 26344.14点，全日成交额为2905.37亿港元；恒生国企指数跌1.07%，报9370.73点；恒生科技指数跌 0.58%，报6257.91点。 东吴证券认为，港股仍在震荡上行趋势中，下行有底。该行指出，美联储降息靴子落地，港股上涨更取 决于产业景气度和基本面边际变化；当前外资对中国资产感兴趣的越来越多，但资金流入还处于早期阶 段；当前港股仍是结构性行情，建议自下而上寻相对低估的个股。 蓝筹股表现 中芯国际(00981)再创新高。截至收盘，涨5.16%，报73.35港元，成交额98.78亿港元，贡献恒指25.48 点。高盛近日指出，将中芯国际H股目标价上调15%至73.1港元。这一乐观预期主要源于对中国IC设计 需求和人工智能趋势的看好，预计这将强劲支撑中芯国际的产量与平均售价。该行同时上调公司2028- 2029年营收及每股收益预测，并指出2025年第三季度营收环比预计增长5%–7%，可能成为短期股价催 化剂。 4. 钢铁股表现活跃。截至收盘，马鞍山钢铁股份(00323)涨4.44%，报2.59港元； ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing down 0.76% at 26,344.14 points and a total trading volume of HKD 290.54 billion [1] - The Hang Seng China Enterprises Index fell by 1.07%, while the Hang Seng Tech Index decreased by 0.58% [1] - Dongwu Securities noted that the Hong Kong market is still in a volatile upward trend, with foreign capital increasingly interested in Chinese assets, although inflows are still in the early stages [1] Blue Chip Performance - Semiconductor company SMIC (00981) reached a new high, closing up 5.16% at HKD 73.35, contributing 25.48 points to the Hang Seng Index [2] - Goldman Sachs raised SMIC's target price by 15% to HKD 73.1, driven by optimism regarding China's IC design demand and AI trends [2] - Other blue-chip stocks like Sunny Optical (02382) and WuXi Biologics (02269) also saw significant gains, while Orient Overseas International (00316) and Techtronic Industries (00669) faced declines [2] Sector Highlights Consumer Electronics - Consumer electronics stocks surged, with notable gains from companies like Hongteng Precision (06088) up 17.83% and Lens Technology (06613) up 12.63% [3] - OpenAI's collaboration with Apple's supply chain companies is expected to drive growth in this sector [3][4] Gold Stocks - Gold stocks collectively rose, with Tongguan Gold (00340) increasing by 7.8% and Lingbao Gold (03330) by 7.53% [4] - Spot gold prices reached a historical high of USD 3,719 per ounce, with a year-to-date increase of 40% [4] Pharmaceutical Stocks - Pharmaceutical stocks showed positive performance, with WuXi AppTec (02268) rising by 8.31% and other companies like Singlomics (01672) and Innovent Biologics (09969) also gaining [5][6] - The National Healthcare Security Administration's new procurement policies are expected to improve the domestic market [6] Steel Stocks - Steel stocks were active, with Maanshan Iron & Steel (00323) up 4.44% [6] - The Ministry of Industry and Information Technology set a growth target of around 4% for the steel industry over the next two years [6] Notable Stock Movements - Yunzhihui Technology (01037) saw a significant increase of 133.96% after announcing a strategic partnership with UBTECH Robotics [7] - Shankou Holdings (00412) rose by 29.76%, with no significant news reported [8] - Dazhong Public Utilities (01635) surged by 21.05%, linked to its investment in Yushu Technology, which is preparing for an IPO [9] - Huiju Technology (01729) increased by 12.18% due to OpenAI's collaboration with its parent company [10] - Liqin Resources (02245) rose by 6.6% as cobalt export restrictions in the Democratic Republic of Congo are set to be lifted [11]

Market Overview - The Hang Seng Index closed down by 0.76%, while the Hang Seng Tech Index decreased by 0.58% [1] - The Hong Kong Tech ETF (159751) rose by 0.91%, and the Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.21% [1] Sector Performance - The communication equipment, electronic devices, and instruments sectors showed strong gains [1] - The life sciences tools and passenger airlines sectors experienced significant declines [1] Individual Stock Movements - Lens Technology increased by 12.63%, Shandong Gold rose by 7.23%, Zhaojin Mining gained 6.35%, WuXi Biologics went up by 6.09%, and SMIC climbed by 5.16% [1] - China National Railway fell by 13.33%, and Longi Green Energy dropped by 7.81% [1] - Shandong High-speed Holdings surged by 29.76%, and MIRXES-B increased by 27.68% [1]

华鑫证券认为，中国创新药出海是创新成果持续涌现和创新效率驱动的结果，全球新药研发向中国转 移，是不可逆转的产业趋势，虽然在短期内或出现波动，但全年增长的趋势不变。 在创新药出海热潮的强力驱动下，国内创新药板块迎来显著复苏。从中报数据来看，较多创新药企成功 实现扭亏为盈，业绩基本面的改善直接点燃了市场对创新药板块的投资热情，板块估值修复行情延续。 港股医药板块午后拉升，恒生医药ETF（159892）涨超2%，药明合联领涨，诺诚健华、药明生物、药 明康德、晶泰控股等跟涨。 2025年以来，中国创新药领域License-out交易频发。据医药魔方数据，2025年上半年，中国License-out 交易共计72笔，交易总金额较2024年全年高出16%，其中单笔金额超过10亿美元的交易达16笔，重磅交 易的落地提升了市场对创新药出海的信心。 ...

Core Insights - The 2025 Cloud Summit will open on September 24, featuring three main forums and three exhibition halls focused on exploring cutting-edge AI directions [1] - AI empowerment is revitalizing technology companies, with Hong Kong-listed firms like Alibaba, Baidu, and Tencent exceeding market expectations in cloud business revenue [1] - The technology sector in Hong Kong is experiencing a strong internal drive, with previous intense competition in sectors like food delivery and automotive cooling down, shifting market focus back to AI narratives [1] Company Developments - Alibaba and other internet leaders are utilizing self-developed chips in AI model training, achieving performance metrics that can compete with similar overseas products, laying a foundation for long-term industry development [1] - The Hong Kong Stock Connect technology ETF (159101) has seen nearly a 9% increase since its launch, with recent continuous capital inflows [1] Market Trends - The AI sector's narrative logic has become the core focus of the market, supported by the strong internal dynamics of the Hong Kong technology sector [1] - Notable stocks such as AAC Technologies, Sunny Optical Technology, WuXi Biologics, and SMIC have shown upward trends, with AAC Technologies leading the gains [1]

Group 1 - The Hang Seng Index fell by 0.99%, the Hang Seng Tech Index dropped by 1.18%, and the Hang Seng China Enterprises Index decreased by 1.3% on September 22, with a half-day trading volume of HKD 164.784 billion [1] - The Hong Kong Stock Connect Technology ETF (159101) experienced a flat performance, while component stocks like AAC Technologies surged over 9%, Sunny Optical Technology rose over 6%, and SMIC and WuXi Biologics increased by over 3% [1] - There has been a continuous net inflow into the Hong Kong Stock Connect Technology ETF for five consecutive trading days, with the last two days seeing a net inflow exceeding HKD 100 million [1] Group 2 - The recent interest rate cut does not signify the end of rate reductions, as the dot plot indicates two more expected cuts by 2025, which will continue to support the Hong Kong stock market and tech sector [2] - The internal drivers for the Hong Kong tech sector remain strong, with reduced competition in industries like food delivery and automotive, and a renewed focus on AI as a core narrative [2] - Recent interim reports from Hong Kong tech companies show that cloud business revenues exceeded market expectations, reinforcing the growth logic driven by AI, alongside strong future capital expenditure plans [2] Group 3 - The Hong Kong Stock Connect Technology ETF (159101) covers major internet giants like Tencent and Alibaba, as well as emerging players like Li Auto and BeiGene, providing a comprehensive investment tool for Chinese tech leaders [3] - The top five holdings account for 57% of the ETF's weight, while the top ten holdings make up 77%, indicating a concentrated yet broad exposure to key sectors including software, hardware, new consumption, innovative pharmaceuticals, and new energy vehicles [3]